Novavax, Inc. (NVAX)
Market Cap | 1.21B |
Revenue (ttm) | 1.25B |
Net Income (ttm) | 478.70M |
Shares Out | 161.97M |
EPS (ttm) | 2.97 |
PE Ratio | 2.50 |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 7,411,595 |
Open | 7.04 |
Previous Close | 6.99 |
Day's Range | 7.02 - 7.48 |
52-Week Range | 5.01 - 23.86 |
Beta | 2.77 |
Analysts | Buy |
Price Target | 19.00 (+155.03%) |
Earnings Date | Aug 7, 2025 |
About NVAX
Novavax, Inc., a biotechnology company, engages in the discovering, developing, and commercializing vaccines to protect against serious infectious diseases in the United States, Europe, and internationally. The company offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adoles... [Read more]
Financial Performance
In 2024, Novavax's revenue was $682.16 million, a decrease of -30.65% compared to the previous year's $983.71 million. Losses were -$187.50 million, -65.60% less than in 2023.
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for NVAX stock is "Buy." The 12-month stock price forecast is $19.0, which is an increase of 155.03% from the latest price.
News

Novavax to Participate in Upcoming Investor Conferences
GAITHERSBURG, Md. , May 29, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that it will participate in the following upcoming investor conferences: Jefferies Global Healthcare Confe...

Novavax: Nuvaxovid FDA Approval Unlocks Several Bullish Stimuli
Novavax's full FDA approval for NUVAXOVID is a transformative milestone, unlocking a $175M Sanofi payment and validating their protein-based vaccine technology. The approval positions Novavax as the o...

Healthy Returns: Novavax scores narrower Covid vaccine approval after delay
The FDA approved Novavax's Covid-19 vaccine but with unusual restrictions.

Top Stock Movers Now: Tesla, AutoZone, Novavax, and More
U.S. equities were down at midday, while the yield on the 10-year Treasury jumped, as the market reacted to Moody's downgrading the U.S. debt rating. The Dow Jones Industrial Average, S&P 500, and Nas...

Novavax Stock Rockets. FDA Finally Had Good News for the Covid-19 Vaccine Maker.
Nuvaxovid had been available under emergency use authorization but the full approval may allow it to better compete with rival vaccine makers.

Novavax shares jump after long-awaited FDA approval of its COVID-19 vaccine
Novavax shares surged more than 17% before the bell on Monday, following the long-delayed approval of its COVID-19 vaccine from the U.S. health regulator, albeit with new conditions.

U.S. FDA Approves BLA for Novavax's COVID-19 Vaccine
Nuvaxovid™ is the only recombinant protein-based, non-mRNA COVID-19 vaccine available in the U.S. Biologics License Application approval triggers $175 million Sanofi milestone payment, with additional...

FDA approves Novavax COVID vaccine with new conditions
The U.S. Food and Drug Administration on Friday approved Novavax's COVID-19 vaccine, but placed additional conditions on individuals who would be able to receive the vaccine.

Novavax, Inc. (NVAX) Presents at BofA Securities 2025 Health Care Conference (Transcript)
Novavax, Inc. (NASDAQ:NVAX) BofA Securities 2025 Health Care Conference May 14, 2025 6:00 PM ET Company Participants John Jacobs - President and CEO Jim Kelly - CFO Ruxandra Draghia-Akli - EVP, Head,...

Novavax: Initiating Hold Rating After Strong, But Misunderstood Q1 2025 Earnings Beat
Initiate coverage on Novavax with a Buy rating; Q1 2025 marks an inflection point with $519M net income and raised revenue guidance to $975M-$1.025B. Novavax's Q1 2025 revenue surged to $667M, driven ...

COVID Vaccine Maker Novavax Stock Soars 16% - Here's Why
On Thursday, Novavax Inc. NVAX reported first-quarter 2025 sales of $667 million, compared to $94 million a year ago, beating the consensus of $343.85 million.

Novavax, Inc. (NVAX) Q1 2025 Earnings Call Transcript
Novavax, Inc. (NASDAQ:NVAX) Q1 2025 Earnings Conference Call May 8, 2025 8:30 AM ET Company Participants Luis Sanay - Vice President, Investor Relations John Jacobs - President and Chief Executive Of...

Why This Shrinking Covid-19 Vaccine Stock Jumped 30%
Novavax has seen its shares plummet since the pandemic because of weakening demand.

Novavax swings to profit on lower expenses related to COVID shots
Novavax on Thursday swung to a first-quarter profit from a year-ago loss, helped by reduced costs related to the development and sale of its COVID-19 vaccines, its only product on the market.

Novavax Reports First Quarter 2025 Financial Results and Operational Highlights
FDA feedback on COVID-19 BLA suggests pathway to approval upon alignment on study parameters for the postmarketing commitment requested by FDA SHIELD-Utah study demonstrates that Nuvaxovid® resulted i...
New vaccine chief rocks pharmaceutical stocks
CNBC's Angelica Peebles joins 'Squawk on the Street' to discuss how the biotech and pharma industry is reacting to a new FDA chief of vaccines appointed by President Trump.

Novavax to Participate in BofA Securities 2025 Health Care Conference
GAITHERSBURG, Md. , May 7, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that it will participate in the BofA Securities 2025 Health Care Conference.

Novavax Announces Significantly Improved Terms for Collaboration and License Agreement with Takeda for Nuvaxovid® in Japan
Improved financial terms for Novavax and streamlined operations will help both companies better meet the needs of the Japanese market Nuvaxovid®, a protein-based, non-mRNA COVID-19 vaccine, will conti...

Novavax to Report First Quarter 2025 Financial Results on May 8, 2025
GAITHERSBURG, Md. , May 1, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced it will report its first quarter 2025 financial results and operational highlights at 8:30 a.m.

Novavax Appoints Charles Newton to Board of Directors
GAITHERSBURG, Md. , April 29, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced the appointment of Charles Newton to its board as an independent director.

FDA asks Novavax to complete new clinical trial for delayed COVID-19 shot, WSJ reports
Federal regulators are asking Novavax to complete an additional clinical trial on its Covid-19 vaccine after previously delaying approval, the Wall Street Journal reported on Friday, citing people fam...

FDA Asks Vaccine Maker to Complete New Clinical Trial for Delayed Covid-19 Shot
A new randomized study could cost Novavax tens of millions of dollars, vaccine experts say.

Insight: As FDA delays Novavax' COVID vaccine approval, patients fight back
Thousands of Americans campaigning for the Novavax COVID-19 booster got some good news this week: the FDA signaled it might still win approval after Health Secretary Robert F. Kennedy Jr cast doubt on...

Novavax's COVID-19 Vaccine Nears FDA Full Approval, Stock Jumps
Novavax, Inc. NAVX stock traded higher on Wednesday.

FDA asks Novavax for commitment on post-approval studies for COVID vaccine
Novavax said on Wednesday the U.S. Food and Drug Administration has sought a commitment from the COVID-19 vaccine maker for additional clinical data if it approves the shot.